
|Videos|January 12, 2016
Dr. Jean Hoffman-Censits on the Results of a Phase II Trial Studying Atezolizumab in Bladder Cancer
Author(s)Jean Hoffman-Censits, MD
Hoffman-Censits says outside of the first-line therapy of cisplatin-based chemotherapy in locally advanced unresectable bladder cancer tumors, there are currently no solutions for disease progression.
Advertisement
Jean Hoffman-Censits, MD, medical oncologist, director, Multidisciplinary Genitourinary Oncology Center, Thomas Jefferson University Hospital, discusses the investigational PD-L1 inhibitor atezolizumab. Hoffman-Censits says outside of the first-line cisplatin-based chemotherapy in locally advanced unresectable bladder cancer tumors, there are currently no solutions for disease progression. She says patients who experienced progression were enrolled into a recent trial testing atezolizumab's efficacy against the malignancy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5



































